Autoantibodies directed against bactericidal/permeability-increasing protein in patients with cystic fibrosis: Association with microbial respiratory tract colonization

Pediatric Infectious Disease Journal

Volumn 19, Issue 3, 2000, Pages 207-212

  Aebi, Christoph ^a   Theiler, Franziska ^a   Aebischer, Carmen Casaulta ^a   Schoeni, Martin H ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Antibody; Autoimmunity; Bactericidal permeability increasing protein; Cystic fibrosis; Pseudomonas aeruginosa

Indexed keywords

AUTOANTIBODY; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; ASPERGILLUS; BACTERIAL COLONIZATION; CHILD; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYSTEM; SEROPREVALENCE; VITAL CAPACITY;

ADOLESCENT; ADULT; AGE FACTORS; ANTIMICROBIAL CATIONIC PEPTIDES; ASPERGILLUS; AUTOANTIBODIES; BLOOD PROTEINS; CYSTIC FIBROSIS; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MEMBRANE PROTEINS; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTIONS; SEROEPIDEMIOLOGIC STUDIES;

EID: 0034068094     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200003000-00006     Document Type: Article

References (25)

1. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNAse I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990;87:9188-92.
2. Balough K, McCubbin M, Weinberger M, Smits W, Ahrens R, Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 1995;20:63-70.
3. Elsbach P. The bactericidal/permeability increasing protein (BPI) in antibacterial host defense. J Leukoc Biol 1998;64:14-8.
4. Ammons S, Aardalen K, Froebel S, Little R. Efficacy of a Domain III-derived peptide from bactericidal/permeability-increasing protein (BPI) in murine disseminated aspergillosis [Abstract B16:29]. In: Proceedings of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28 to October 1, 1997. Washington, DC: American Society for Microbiology, 1997.
5. Weiss J, Olsson I. Cellular and subcellular localization of the bactericidal/permeability increasing protein of neutrophils. Blood 1987;69:652-9.
6. Weersink AJ, van Kessel KP, van den Tol ME, et al. Human granulocytes express a 55-kDa lipopolysaccharide-binding protein on the cell surface that is identical to the bactericidal/ permeability-increasing protein. J Immunol 1993;150:253-63.
7. Weissrauch Y, Foreman A, Shu C, et al. Extracellular accumulation of potentially microbicidal bactericidal/permeability increasing protein and p15s in an evolving sterile rabbit peritoneal inflammatory exsudate. J Clin Invest 1995;95: 1916-24.
8. Lambert L, Mitchell C, Scannon P. Recombinant bactericidal/ permeability-increasing protein (rBPI-21) is bactericidal in vitro against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients [Abstract E-149]. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September, 1997.
9. Zhao MH, Jayne DRW, Ardiles LG, Culley F, Hodson ME, Lockwood CM. Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis. Q J Med 1996;89:259-65.
10. Sediva A, Bartunkova J, Kolarova I, et al. Antineutrophil cytoplasmic autoantibodies (ANCA) in children with cystic fibrosis. J Autoimmun 1998;11:185-90.
11. Taccetti G, Campana S, Turchini S, Chiappini E, Marianelli L. ANCA and anti-BPI antibodies in cystic fibrosis patients [Abstract PS6-26]. Presented at the 22nd European Cystic Fibrosis Conference, Berlin, June, 1998.
12. Messore B, De Rose V, Grosso B, et al. Anti-BPI antibodies in cystic fibrosis [Abstract PS6-8]. Presented at the 22nd European Cystic Fibrosis Conference, Berlin, June 13 to 19, 1998:138.
13. Gibson LF, Cooke PE. A test for the concentration of electrolytes in sweat of CF of the pancreas utilizing pilocarpine iontophoresis. Pediatrics 1959;23:545-9.
14. Kraemer R, Ruedeberg A, Klaey M, Rossi E. Relationship between clinical conditions, radiographic findings and pulmonary function in patients with cystic fibrosis. Helv Paediatr Acta 1979;34:417-28.
15. Chrispin AR, Norman AP. The systematic evaluation of the chest radiograph in cystic fibrosis. Pediatr Radiol 1974;2:101-6.
16. Cystic Fibrosis Foundation. Microbiology and infectious disease in cystic fibrosis. In: Consensus conference: concepts of care. vol 5. sect 1. Bethesda, MD: Cystic Fibrosis Foundation, 1994.
17. Nelson LA, Callerance ML, Schwartz RM. Aspergillus and atopy in cystic fibrosis. Am Rev Respir Dis 1979;120:863-73.
18. Zhao MH, Jones SJ, Lookwood CM. Bactericidal/permeability increasing protein (BPI) is an important antigen for anti- neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis. Clin Exp Immunol 1995;99:49-56.
19. Kraemer R, Birrer P, Liechti-Gallati S. Genotype-phenotype association in infants with cystic fibrosis at the time of diagnosis. Pediatr Res 1998;44:920-6.
20. Sediva A, Koralova I, Bartunkova J. Antineutrophil cytoplasmic antibodies in children. Eur J Pediatr 1998;157:987-91.
21. Taccetti G, Chiappini E, Campana S, Turchini S, Marianelli L. Autoantibodies against bactericidal/permeability-increasing protein in cystic fibrosis patients [Abstract 439]. Presented at the North American Cystic Fibrosis Conference, Toronto, October 15 to 18, 1998. Montreal: Cystic Fibrosis Foundation, 1998.
22. Mahadeva R, Dunn AC, Westerbeek RC. et al. Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease. Clin Exp Immunol 1999;117:561-7.
23. Dunn AC, Walmsley RS, Dedrick RL, Wakefield AJ, Lockwood CM. Anti-neutrophil cytoplasmic antibodies (ANCA) to bactericidal/permeability-increasing protein recognize the carboxyl terminal domain. J Infect 1999;39:81-7.
24. Mahadeva R, Zhao MH, Steward S, et al. Vasculitis and bronchiectasis in a patient with antibodies to bactericidal/ permeability increasing protein and alpha 1-antitrypsin deficiency. Chest 1997;112:1699-701.
25. Stoffel MP, Csernok E, Herzberg C, Johnston T, Carroll SF, Gross WL. Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders. Clin Exp Immunol 1996;104:54-9.